כל המחקרים
גיוסשלב 3התערבותי

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

This study is investigating a new medication called Votoplam for people who have early symptoms of Huntington's disease. The main goals are to find out how safe Votoplam is, if people taking it tolerate it well, and if it can slow down the speed at which Huntington's disease gets worse. To do this, some participants will receive Votoplam, while others will get a placebo (a dummy medicine with no active ingredients). This is a 'blinded' study, meaning neither the participants nor their doctors will know who is receiving which treatment until the study is over. The study involves taking the medicine for up to 3 years and includes regular check-ups.

במבט חטוף

סטטוס
גיוס
שלב
שלב 3
נותן חסות
נוברטיס פרמצבטיקה
יעד הרשמה
770
התחל
24 במרץ 2026
השלמה משוערת
30 Apr 2030

על מה המחקר הזה?

Huntington's disease is a condition that affects the brain and can lead to problems with movement, thinking, and mental health. This study is testing a new medicine called Votoplam to see if it can help people who are in the early stages of the disease. Researchers want to understand if Votoplam can make a real difference in slowing down how quickly the disease progresses.

To make sure the results are fair and accurate, the study uses a method called 'blinded' treatment. This means that some participants will receive Votoplam, and others will receive a 'placebo' – which looks exactly like the study medicine but doesn't contain any active ingredients. Neither you nor your study doctor will know which one you are taking until the study has finished. This helps to ensure that any improvements or side effects observed can be directly linked to the actual medicine.

The information gathered from this study will be crucial in deciding if Votoplam could become a new treatment option for people living with Huntington's disease. It's an important step in ongoing research to find better ways to manage this condition.

נקודות עיקריות

  • This study is testing a new medicine called Votoplam for early Huntington's disease.
  • It aims to see if Votoplam is safe, well-tolerated, and can slow disease progression.
  • Participants will receive either Votoplam or a placebo for up to 3 years.
  • The study includes a screening phase, a treatment phase, and a safety follow-up.
  • Eligibility is for adults aged 21-70 with genetically confirmed early-symptomatic Huntington's.
  • Your decision to join is voluntary, and you can withdraw at any time.

מי עשוי להיות זכאי?

To be considered for this study, you need to be an adult between the ages of 21 and 70. You must have a confirmed diagnosis of Huntington's disease through genetic testing, and it should be clear that you are in the earlier stages where you are experiencing symptoms, but are still able to walk. The genetic test also needs to show a specific number (40 or more) in your CAG repeat length.

There are also some reasons why you wouldn't be able to join. For example, if you've had certain brain surgeries for Huntington's, or if you have specific heart problems or certain infections like active hepatitis or HIV, you wouldn't be eligible. Women who could become pregnant are only able to join if they meet certain criteria, such as having had specific surgeries that prevent pregnancy, or if they are past menopause.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Are you between 21 and 70 years old?
  2. Have you been diagnosed with Huntington's disease through genetic testing?
  3. Do you have a CAG repeat length of 40 or more?
  4. Are you still able to walk?
  5. Are you free from certain heart conditions or active infections like hepatitis or HIV?
  6. If you are a woman of childbearing potential, have you had specific surgeries to prevent pregnancy or are you post-menopausal?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you decide to take part, your first step will be a 'Screening Period' which can last up to 42 days. During this time, doctors will do tests and checks to make sure the study is right for you. If you qualify, you'll then enter the 'Double-blind Treatment Period', where you'll be given either Votoplam or a dummy medicine. You could be on this treatment for up to 3 years, although not everyone will complete the full 3 years.

Throughout the treatment period, you'll have regular visits to the clinic so doctors can monitor your health and see how you're responding to the treatment. After you finish the treatment, there will be one final 'Safety Follow-up' visit or phone call about a month later. This is to check on your health one last time, especially if you're not continuing into a separate, longer-term study.

סיכונים ותועלות פוטנציאליים

Taking part in any clinical trial has potential benefits and potential risks. A potential benefit of this study is that Votoplam might slow down the progression of Huntington's disease, and you would be contributing valuable information to help others in the future. However, there's no guarantee you'll receive the active drug or that it will help you. Potential risks could include side effects from the medication, which would be monitored closely by the study team. You always have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (117)

  • University of Alabama Birmingham
    מיקוד מאומת
    בירמינגהם, ארצות הברית· גיוס
  • Univ of Arkansas for Med Sciences
    מיקוד מאומת
    ליטל רוק, ארצות הברית· גיוס
  • University of CA San Diego
    מיקוד מאומת
    לה הויה, ארצות הברית· גיוס
  • UC Davis Health System
    מיקוד מאומת
    סקרמנטו, ארצות הברית· גיוס
  • UCSF
    מיקוד מאומת
    סן פרנסיסקו, ארצות הברית· גיוס
  • Stanford Healthcare
    מיקוד מאומת
    סטנפורד, ארצות הברית· גיוס
  • CenExcel Rocky Mtn Clin Research
    מיקוד מאומת
    Englewood, United States· גיוס
  • U Conn Health
    מיקוד מאומת
    Farmington, United States· גיוס
  • Georgetown University
    מיקוד מאומת
    וושינגטון די.סי., ארצות הברית· גיוס
  • UM Department Of Neurology
    מיקוד מאומת
    מיאמי, ארצות הברית· גיוס
  • University Of South Florida
    מיקוד מאומת
    טמפה, ארצות הברית· גיוס
  • Grady Memorial Hospital and Clinics
    מיקוד מאומת
    אטלנטה, ארצות הברית· גיוס

שאלות נפוצות

What does 'blinded' mean in a study?

It means neither you nor your study doctor will know if you are receiving the real medicine or a dummy medicine (placebo) until the study is over.

כמה זמן אהיה במחקר?

The treatment part of the study could last up to 3 years, but not everyone will stay in for the full period. There's also a screening period before treatment and a follow-up check after.

מהו 'פלצבו'?

A placebo is a dummy medicine that looks just like the real drug but contains no active ingredients. It helps researchers compare the effects of the active medicine fairly.

האם אני יכול לעזוב את המחקר אם אשנה את דעתי?

Yes, you are free to leave the study at any time, for any reason. Your decision will not affect your usual medical care.

מהי מחלת הנטינגטון?

Huntington's disease is a condition that affects the brain, causing parts of it to slowly stop working over time. This can lead to problems with movement, thinking, and emotions.

כיצד לגלות עוד

נוברטיס פרמצבטיקה

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "A Study to Investigate the Efficacy, Safety and Tolerability…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.